Catalyst Wire Dossier Catalyst Wire Dossier

Human embryonic stem cell-derived retinal pigment epithelium cell therapy

· Astellas Institute for Regenerative Medicine
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Human embryonic stem cell-derived retinal pigment epithelium cell therapy, covering 2026-04-16 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy [Phase 1, Phase 2]

See pricing